Mylan’s Stock Jumps After $465 Million EpiPen SettlementBy
Shares rise as much as 13%, rebound from three-year low
Company also gets inquiry from SEC asking about Medicaid
Mylan NV climbed as much as 13 percent after the drugmaker agreed to pay the U.S. government $465 million in a swift settlement over how it charged Medicaid for its allergy shot EpiPen.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.